2019 Annual Meeting of the European Association for the Study of the Liver*

April 10-14, 2019; Vienna, Austria
Get the latest hepatitis and NASH data with rapid Capsule Summaries and downloadable slidesets covering key studies from Vienna.

Highlights

Capsule Summary Slidesets

Male sex and high HBV DNA were associated with increased flare risk in this single-center, randomized phase IV study.

Released: April 15, 2019

Patients treated with VK2809 for 12 weeks showed significantly reduced LDL-C and liver fat content vs those treated with placebo.

Released: April 22, 2019

Obeticholic acid showed significant, dose-dependent improvement in the primary endpoint of fibrosis improvement with no worsening of NASH in this interim analysis of a large randomized trial.

Released: April 16, 2019

Although this trial did not meet the primary endpoint of decreasing mean hepatic venous pressure gradient in patients with NASH cirrhosis and severe portal hypertension, positive signals were seen that support additional exploration of emricasan in patients with severe portal hypertension.

Released: April 17, 2019

Reduced risk of HCC with TDF vs ETV maintained in propensity score–weighted analysis of Hong Kong cohort including more than 29,000 patients with CHB.

Released: April 17, 2019

Large observational study reported variations in DAA efficacy among patients with genotype 3 HCV and compensated cirrhosis.

Released: April 16, 2019

Large database study finds significant gaps remain across all stages of the HCV care cascade in US.

Released: April 15, 2019

This pilot study conducted in a rural Egyptian village established the feasibility of a simplified, same-day, test-and-treat program for HCV and HBV infection.

Released: April 15, 2019

High uptake of HCV testing and treatment noted in this observational cohort study, although female sex and not currently receiving OST were each associated with reduced treatment uptake.

Released: April 15, 2019

Simplified monitoring schedule resulted in similar safety and efficacy but was not noninferior to standard monitoring for SVR12 in ITT population.

Released: April 15, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
AbbVie
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue